Enthera Pharmaceuticals is a clinical-stage biotech based in Milan, Italy, developing first-in-class biologics that aim to do something most autoimmune drugs do not: restore the organ, not just calm the inflammation. Its lead antibody, ebrasodebart (Ent001), blocks the IGFBP3/TMEM219 pathway, a signal that drives apoptosis of intestinal stem cells in the gut and insulin-producing beta cells in the pancreas. The company targets inflammatory bowel disease and type 1 diabetes, two conditions with deep unmet need, and is advancing the program through Phase 1 clinical trials.
Lisa M. Olson, Ph.D., is a biopharmaceutical research leader who became CEO of Milan-based clinical-stage biotech Enthera Pharmaceuticals in January 2024, after years on its board and as chair of its Scientific Advisory Board. Across two decades in immunology drug discovery - 15 years at AbbVie/Abbott where she helped advance 15 molecules into the clinic including Rinvoq, plus roles at Pfizer and as Chief Scientific Officer of Magenta Therapeutics - she has built a career turning biology into medicine. At Enthera she is steering the clinical development of Ent001, a first-in-class antibody targeting the IGFBP3/TMEM219 pathway for inflammatory bowel disease and type 1 diabetes.